Coverage dated November 7, 2026 to November 9, 2026

STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

Headline from STAT

Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.

STAT's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Reports & sources

3 articles, oldest first.

  1. Bloomberg

    Novartis Abandons Heart Drug After Surprising Failure in Key Study (opens Bloomberg)

    Published

    Bloomberg's feed description

    Novartis AG is largely abandoning an experimental drug analysts once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and cardiovascular deaths.

  2. STAT

    STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy (opens STAT)

    Published

    STAT's feed description

    Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.

  3. STAT

    STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more (opens STAT)

    Published

    STAT's feed description

    Novartis is largely abandoning a drug once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and deaths

STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy | Since Then